Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $95.00 Price Target at Morgan Stanley
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $95.00 Price Target at Morgan Stanley
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its target price lowered by Morgan Stanley from $100.00 to $95.00 in a report published on Friday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company's stock.
據Benzinga報道,在週五發佈的一份報告中,摩根士丹利將Ultragenyx製藥公司(納斯達克:Rare-Get評級)的目標價從100.00美元下調至95美元。該公司目前對這家生物製藥公司的股票有增持評級。
Several other brokerages also recently issued reports on RARE. Cowen lowered their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Cowen lowered their target price on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research note on Thursday, November 3rd. HC Wainwright restated a buy rating and set a $82.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 30th. Wedbush restated a neutral rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, October 13th. Finally, Robert W. Baird upgraded Ultragenyx Pharmaceutical from a neutral rating to an outperform rating and lowered their target price for the company from $63.00 to $50.00 in a research note on Thursday, November 3rd. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $91.69.
其他幾家券商最近也發佈了關於Rare的報告。考恩在11月3日星期四的一份報告中將他們對Ultragenyx製藥公司的目標價從86.00美元下調至65.00美元。考恩在11月3日週四的一份研究報告中將他們對Ultragenyx Pharmtics的目標價從86.00美元下調至65.00美元。12月30日星期五,HC Wainwright在一份研究報告中重申了買入評級,併為Ultragenyx製藥公司的股票設定了82.00美元的目標價。韋德布什在10月13日星期四的一份研究報告中重申了對Ultragenyx製藥公司股票的中性評級。最後,Robert W.Baird在11月3日週四的一份研究報告中將Ultragenyx Pharmtics的評級從中性上調至表現優於大盤,並將該公司的目標價從63.00美元下調至50.00美元。三位股票研究分析師對該股的評級為持有,十位分析師給予該公司買入評級。根據MarketBeat.com的數據,該公司目前的平均評級為中等買入,平均目標價為91.69美元。
Ultragenyx Pharmaceutical Trading Down 3.4 %
Ultragenyx製藥公司股價下跌3.4%
Shares of NASDAQ RARE opened at $45.73 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $33.36 and a 12-month high of $85.53. The stock has a fifty day moving average price of $43.04 and a 200 day moving average price of $43.66.
上週五,納斯達克稀有的股價開盤報45.73美元。Ultragenyx Pharmtics的12個月低點為33.36美元,12個月高位為85.53美元。該股的50日移動均價為43.04美元,200日移動均價為43.66美元。
Insider Transactions at Ultragenyx Pharmaceutical
Ultragenyx製藥公司的內幕交易
In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm's stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $43.96, for a total value of $89,282.76. Following the transaction, the chief accounting officer now owns 16,197 shares of the company's stock, valued at $712,020.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.
在Ultragenyx製藥公司的其他新聞中,首席財務官西奧多·艾倫·惠曾加在一筆日期為12月21日星期三的交易中出售了2031股公司股票。這些股票的平均價格為43.96美元,總價值為89,282.76美元。交易完成後,這位首席會計官現在持有該公司16,197股股票,價值712,020.12美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。公司內部人士持有該公司6.70%的股份。
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
對衝基金入股Ultragenyx製藥公司
A number of large investors have recently bought and sold shares of the business. Lazard Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 240 shares during the last quarter. Chartwell Investment Partners LLC lifted its holdings in Ultragenyx Pharmaceutical by 3.6% in the third quarter. Chartwell Investment Partners LLC now owns 7,623 shares of the biopharmaceutical company's stock worth $316,000 after acquiring an additional 268 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Virtus ETF Advisers LLC now owns 4,895 shares of the biopharmaceutical company's stock valued at $292,000 after buying an additional 345 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Ultragenyx Pharmaceutical by 2.1% during the second quarter. Arizona State Retirement System now owns 17,863 shares of the biopharmaceutical company's stock valued at $1,066,000 after buying an additional 359 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 151.0% during the third quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 361 shares during the last quarter. Institutional investors own 93.17% of the company's stock.
一些大型投資者最近買賣了該公司的股票。Lazard Asset Management LLC在第一季度增持了36.6%的Ultragenyx Pharmtics股份。Lazard Asset Management LLC在上個季度增持了240股後,現在擁有這家生物製藥公司896股股票,價值6.4萬美元。Chartwell Investment Partners LLC在第三季度增持了Ultragenyx Pharmtics 3.6%的股份。Chartwell Investment Partners LLC現在擁有這家生物製藥公司7623股股票,價值31.6萬美元,在上個季度額外收購了268股。Virtus ETF Advisers LLC在第二季度將其在Ultragenyx Pharmtics的股票持有量增加了7.6%。Virtus ETF Advisers LLC現在擁有4,895股這家生物製藥公司的股票,價值29.2萬美元,此前在上個季度又購買了345股。亞利桑那州退休系統在第二季度將Ultragenyx Pharmtics的股票持有量增加了2.1%。亞利桑那州退休系統現在擁有17,863股這家生物製藥公司的股票,價值1,066,000美元,在上個季度又購買了359股。最後,Signaturefd LLC在第三季度將其持有的Ultragenyx製藥公司的股票增加了151.0%。Signaturefd LLC現在擁有600股這家生物製藥公司的股票,價值2.5萬美元,在上個季度又購買了361股。機構投資者持有該公司93.17%的股票。
About Ultragenyx Pharmaceutical
關於Ultragenyx製藥公司
(Get Rating)
(獲取評級)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Ultragenyx製藥公司是一家生物製藥公司,從事治療嚴重罕見和超罕見遺傳病的新產品的識別、收購、開發和商業化。其產品包括Mepsevii和Crysvita。Mepsevii是一種靜脈酶替代療法,用於治療粘多糖病VII。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免費獲取StockNews.com關於Ultragenyx製藥公司的研究報告(Rare)
- 市場回顧周-1/30-2/3
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Ultragenyx藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ultragenyx製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。